Boehringer Ingelheim, Evotec and bioMérieux forms JV Aurobac to fight antimicrobial resistance
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The AICVD tool can predict the risk of cardiovascular disease.
Mittal has previously managed Multiple backed Vikram Hospital as CEO and was associated with Fortis Escorts Heart Institute as zonal director.
People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.
Medicines, including insulin, to be available in 40 lower-income countries
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
Meets the growing need for US-based API solubility and bioavailability enhancement services
Govt committed to supporting pharma companies with industry-friendly policies
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Subscribe To Our Newsletter & Stay Updated